Our mandate includes the support of several CE-IVD diagnostic platforms in order to maintain diagnostic capabilities for patients and caregivers even on difficult samples. In challenging diagnostic sensitivity and specificity of our biomarker portfolio we aim to maintain a deepening understanding of difficult cases whilst keeping a holistic view on all samples and all processes.

In diligent obtainment of accreditation for biomarkers across platforms and between biological specimens we build a solid portfolio of diagnostic tests to match the rapidly evolving fields of solid and liquid biopsy driven hemato-oncology.

Our quality management system therein maintains an expanding set of devices, platforms and procedures allowing for point of care diagnostics through to whole exome sequencing. We offer more than a dozen Companion Diagnostic (CDx) tests and all prognostic and predictive biomarkers achieve ISO15189 status.